Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease
- 26 October 2020
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (37) , 4721-4737
Abstract
Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.Keywords
This publication has 181 references indexed in Scilit:
- Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trialThe Lancet Neurology, 2013
- Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in MicePLOS ONE, 2013
- Meta‐analysis of early nonmotor features and risk factors for Parkinson diseaseAnnals of Neurology, 2012
- Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpressionMolecular and Cellular Neuroscience, 2012
- Solvent exposures and parkinson disease risk in twinsAnnals of Neurology, 2011
- Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER)Movement Disorders, 2010
- Mechanisms Underlying Inflammation in NeurodegenerationCell, 2010
- The pathobiology of splicingThe Journal of Pathology, 2009
- Magnetic nanoparticles for theragnosticsAdvanced Drug Delivery Reviews, 2009
- Frequency of New-Onset Pathologic Compulsive Gambling or Hypersexuality After Drug Treatment of Idiopathic Parkinson DiseaseMayo Clinic Proceedings, 2009